Pharmaceutical firm Merck reported a net income of $906m, or $0.30 per share for the second quarter ended on 30 June 2013 compared to $1.8bn, or $0.58 per share in 2012. Total revenue for the second quarter ended on 30 June 2013 was ...
Tags: Merck, Pharmaceutical firm
Japan-based Takeda Pharma has received positive CHMP opinion for its three new type 2 diabetes therapies from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The therapies include Vipidia ...
Tags: Therapies, CHMP Opinion
GlaxoSmithKline (GSK) has announced Health Canada approval of a BRAF-inhibitor, Tafinlar, and a first in class MEK-inhibitor, Mekinist, for melanoma patients with BRAF V600 mutation. Both, Tafinlar (dabrafenib mesylate) and Mekinist ...
Tags: Melanoma Drugs, Medicine
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has confirmed its opinion for European marketing authorization of Pfizer's Xeljanz (tofacitinib citrate). Xeljanz is a novel, oral Janus kinase ...
Henkel AG & Co. KGaA has been awarded a patent for an anti-corrosion coating composition for a metal substrate comprised of no electrically conductive polymers and at least one non-electrically conductive film forming copolymer; a nitrogen ...
Tags: Coating, Construction
The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
Janssen Research & Development is seeking FDA approval for use of ibrutinib in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The ...
Tags: FDA Approval, Janssen
The US FDA has accepted to review Bristol-Myers Squibb Company and Pfizer's Eliquis (apixaban) supplemental new drug application for prophylaxis of deep vein thrombosis (DVT) subsequent to hip or knee replacement surgery. The application ...
Tags: Drug Application, Medicine
The firm did not disclose who produced the bottle when asked by PN. However, it said that its absinthe spirit can be damaged quickly in traditional bottles. La Fée said that it created a "unique new bottle to ensure the delicate ...
Oncology-focused drug development company Curis has secured US patent protecting intellectual property rights of its phosphoinositide 3-kinase (PI3K) - histone deacetylase (HDAC) inhibitor, CUDC-907. The patent covers the method of ...
Tags: Health&Medicine, Curis, US
Teva Pharmaceutical Industries has signed an agreement to purchase pharmaceutical and drug delivery company, MicroDose Therapeutx, to strengthen its respiratory franchise. The deal involves acquisition of all of MicroDose's outstanding ...
Biopharmaceutical company Gilead Sciences has obtained priority review status for Sofosbuvir new drug application (NDA) from the FDA for the treatment of hepatitis C infection (HCV). The investigational product is an oral nucleotide ...
Tags: Gilead, Sofosbuvir NDA
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's Tafinlar (dabrafenib) and Mekinist (trametinib) as single-agent therapies for unresectable or metastatic melanoma with BRAF V600E mutation. Tafinlar is not indicated ...
Astellas Pharma and Medivation have announced the Health Canada approval of Xtandi (enzalutamide) capsules to treat metastatic castration-resistant prostate cancer. The oral, once-daily androgen receptor inhibitor is indicated for ...
Tags: Astellas Pharma, Medicine
Mitsubishi Tanabe Pharma is seeking manufacturing and marketing approval of TA-7284 (generic name: canagliflozin) in Japan. The company filed a new drug application to the Ministry of Health, Labor and Welfare in Japan for TA-7284 to ...
Tags: Mitsubishi, canagliflozin